C07K 16/2851
Against the lectin superfamily
Official title: {against the lectin superfamily, e.g. CD23, CD72}
C07K16/2851 (Against the lectin superfamily) appears on 722 US grants and 1,489 published applications in this corpus.
Search patents in C07K- Granted patents
- 722
- Published applications
- 1,489
- Assignees
- 568
- Inventors
- 2,576
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 3 | 0 |
| 1994 | 4 | 0 |
| 1995 | 4 | 0 |
| 1996 | 1 | 0 |
| 1997 | 7 | 0 |
| 1998 | 19 | 0 |
| 1999 | 9 | 0 |
| 2000 | 9 | 0 |
| 2001 | 16 | 3 |
| 2002 | 5 | 17 |
| 2003 | 7 | 25 |
| 2004 | 3 | 22 |
| 2005 | 7 | 31 |
| 2006 | 8 | 22 |
| 2007 | 7 | 20 |
| 2008 | 8 | 29 |
| 2009 | 9 | 35 |
| 2010 | 11 | 29 |
| 2011 | 24 | 44 |
| 2012 | 18 | 54 |
| 2013 | 27 | 44 |
| 2014 | 23 | 55 |
| 2015 | 37 | 58 |
| 2016 | 39 | 75 |
| 2017 | 40 | 63 |
| 2018 | 43 | 69 |
| 2019 | 43 | 96 |
| 2020 | 41 | 90 |
| 2021 | 46 | 111 |
| 2022 | 31 | 100 |
| 2023 | 40 | 89 |
| 2024 | 45 | 111 |
| 2025 | 61 | 94 |
| 2026 | 26 | 103 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Anti-galectin 3 antibodies and their use in epilepsy and related diseases6 Oct 2026US 12,752,015 B2Sunmed Therapeutic Limited
- Bispecific single chain antibodies with specificity for high molecular weight target antigens15 Sep 2026US 12,735,484 B2Amgen Research (Munich) GmbH
- KLRB1 binding agents and methods of use thereof1 Sep 2026US 12,723,089 B2The Brigham and Women S Hospital, Inc.
- KLRB1 binding agents and methods of use thereof1 Sep 2026US 12,723,090 B2The Brigham and Women S Hospital, Inc.
- RNAi constructs for inhibiting ASGR1 expression and methods of use thereof1 Sep 2026US 12,723,248 B1Amgen Inc.
- Use of alpha-2,6-sialylated immunoglobulin in preventing or treating dry eye syndrome or inflammatory eye diseases8 Oct 2026US 2026/0308261 A1Konkuk University Industrial Cooperation Corp.
- Anti-cd161 antibodies and methods of use thereof8 Oct 2026US 2026/0308262 A1Novasenta, Inc.
- Molecule specifically acting in a tissue where a cell death being observed1 Oct 2026US 2026/0297192 A1
- Light-expressing immunoresponsive cells and uses thereof1 Oct 2026US 2026/0297517 A1Memorial Sloan Kettering Cancer Center
- Car-t cell targeting cll1, preparation method therefor and use thereof1 Oct 2026US 2026/0297519 A1Carbiogene Therapeutics Co., Ltd.
Most cited
By later US patents
- Method of making transgenic mice lacking endogenous heavy chains1,057US 5,939,598 AAbgenix, Inc. · 1999
- Human antibodies derived from immunized xenomice1,057US 6,075,181 AAbgenix, Inc. · 2000
- Human antibodies derived from immunized xenomice943US 6,150,584 AAbgenix, Inc. · 2000
- Generation of xenogeneic antibodies639US 6,114,598 AAbgenix, Inc. · 2000
- Generation of Xenogenetic antibodies561US 6,162,963 AAbgenix, Inc. · 2000